Logo image of DMK

DMK PHARMACEUTICALS CORP (DMK) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:DMK - US00547W3079 - Common Stock

0.232 USD
+0 (+0.91%)
Last: 2/6/2024, 8:05:16 PM
0.1665 USD
-0.07 (-28.23%)
After Hours: 2/6/2024, 8:05:16 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to DMK. DMK was compared to 192 industry peers in the Pharmaceuticals industry. DMK may be in some trouble as it scores bad on both profitability and health. DMK is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year DMK has reported negative net income.
DMK had a negative operating cash flow in the past year.
In the past 5 years DMK always reported negative net income.
DMK had a negative operating cash flow in each of the past 5 years.
DMK Yearly Net Income VS EBIT VS OCF VS FCFDMK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

DMK's Return On Assets of -248.15% is on the low side compared to the rest of the industry. DMK is outperformed by 93.56% of its industry peers.
Industry RankSector Rank
ROA -248.15%
ROE N/A
ROIC N/A
ROA(3y)-173.97%
ROA(5y)-129.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DMK Yearly ROA, ROE, ROICDMK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 1K -1K 2K 3K 4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DMK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DMK Yearly Profit, Operating, Gross MarginsDMK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K -1.5K -2K

More info and screens

1

2. Health

2.1 Basic Checks

DMK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DMK has about the same amount of shares outstanding.
There is no outstanding debt for DMK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DMK Yearly Shares OutstandingDMK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M 2M
DMK Yearly Total Debt VS Total AssetsDMK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

DMK has an Altman-Z score of -60.09. This is a bad value and indicates that DMK is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of DMK (-60.09) is worse than 94.55% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -60.09
ROIC/WACCN/A
WACC8.88%
DMK Yearly LT Debt VS Equity VS FCFDMK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 0.58 indicates that DMK may have some problems paying its short term obligations.
The Current ratio of DMK (0.58) is worse than 92.57% of its industry peers.
DMK has a Quick Ratio of 0.58. This is a bad value and indicates that DMK is not financially healthy enough and could expect problems in meeting its short term obligations.
DMK has a Quick ratio of 0.54. This is amonst the worse of the industry: DMK underperforms 93.07% of its industry peers.
Industry RankSector Rank
Current Ratio 0.58
Quick Ratio 0.54
DMK Yearly Current Assets VS Current LiabilitesDMK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 37.96% over the past year.
The Revenue has grown by 160.36% in the past year. This is a very strong growth!
Measured over the past years, DMK shows a very negative growth in Revenue. The Revenue has been decreasing by -18.29% on average per year.
EPS 1Y (TTM)37.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.73%
Revenue 1Y (TTM)160.36%
Revenue growth 3Y-40.07%
Revenue growth 5Y-18.29%
Sales Q2Q%-99.4%

3.2 Future

The Earnings Per Share is expected to grow by 25.25% on average over the next years. This is a very strong growth
Based on estimates for the next years, DMK will show a very strong growth in Revenue. The Revenue will grow by 53.75% on average per year.
EPS Next Y64.16%
EPS Next 2Y38.62%
EPS Next 3Y25.25%
EPS Next 5YN/A
Revenue Next Year-68.82%
Revenue Next 2Y-0.76%
Revenue Next 3Y53.75%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
DMK Yearly Revenue VS EstimatesDMK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
DMK Yearly EPS VS EstimatesDMK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2023 2024 2025 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

DMK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DMK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DMK Price Earnings VS Forward Price EarningsDMK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DMK Per share dataDMK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

A more expensive valuation may be justified as DMK's earnings are expected to grow with 25.25% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.62%
EPS Next 3Y25.25%

More info and screens

0

5. Dividend

5.1 Amount

DMK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DMK PHARMACEUTICALS CORP

NASDAQ:DMK (2/6/2024, 8:05:16 PM)

After market: 0.1665 -0.07 (-28.23%)

0.232

+0 (+0.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2023-11-14/amc
Earnings (Next)03-14 2024-03-14/bmo
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.09%
Ins Owner Change0%
Market Cap2.34M
Revenue(TTM)3.62M
Net Income(TTM)-22.23M
Analysts80
Price Target1.53 (559.48%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.65
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-9.17
EYN/A
EPS(NY)-0.97
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.93
OCFYN/A
SpS0.36
BVpS-0.49
TBVpS-0.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -248.15%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-173.97%
ROA(5y)-129.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.2%
Cap/Sales 2.49%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.58
Quick Ratio 0.54
Altman-Z -60.09
F-Score5
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)52.33%
Cap/Depr(5y)73.76%
Cap/Sales(3y)34.55%
Cap/Sales(5y)28.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.73%
EPS Next Y64.16%
EPS Next 2Y38.62%
EPS Next 3Y25.25%
EPS Next 5YN/A
Revenue 1Y (TTM)160.36%
Revenue growth 3Y-40.07%
Revenue growth 5Y-18.29%
Sales Q2Q%-99.4%
Revenue Next Year-68.82%
Revenue Next 2Y-0.76%
Revenue Next 3Y53.75%
Revenue Next 5YN/A
EBIT growth 1Y12.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y74.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y74.31%
OCF growth 3YN/A
OCF growth 5YN/A

DMK PHARMACEUTICALS CORP / DMK FAQ

What is the fundamental rating for DMK stock?

ChartMill assigns a fundamental rating of 2 / 10 to DMK.


Can you provide the valuation status for DMK PHARMACEUTICALS CORP?

ChartMill assigns a valuation rating of 1 / 10 to DMK PHARMACEUTICALS CORP (DMK). This can be considered as Overvalued.


How profitable is DMK PHARMACEUTICALS CORP (DMK) stock?

DMK PHARMACEUTICALS CORP (DMK) has a profitability rating of 0 / 10.


What is the expected EPS growth for DMK PHARMACEUTICALS CORP (DMK) stock?

The Earnings per Share (EPS) of DMK PHARMACEUTICALS CORP (DMK) is expected to grow by 64.16% in the next year.